Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been fully informed about the study and have agreed to take part by signing a consent form, after having enough time to think it over.
- Men aged 50 years or older.
- People whose PSA blood test result is 15 ng/mL or below.
- People who have been diagnosed with prostate cancer that has not spread beyond the prostate (stage T1 or T2), with a Gleason score of 7 or lower (a measure of how the cancer cells look under a microscope).
- People whose treatment plan — either targeted, half-gland, or full-gland HIFU (a type of ultrasound-based treatment) — has been approved by a specialist team meeting.
- People who are enrolled in Medicare or an equivalent health coverage plan.
- People who have had a specific type of detailed prostate MRI scan (multiparametric MRI) taken within the 180 days before the procedure, with results that can be clearly read and assessed.
Who may not be able to join:
- People with an anaesthetic risk score (ASA score) greater than 3, meaning those considered to be at higher risk during surgery (confirm with trial site).
- People who have previously had brachytherapy (a type of internal radiation treatment) for prostate cancer.
- People who are legally protected adults, such as those under guardianship or a similar legal arrangement.
- People for whom HIFU treatment is not suitable due to large calcium deposits in the prostate that block the ultrasound waves needed for the procedure.
- People who have permanent radioactive implants in the wall of the rectum (the lower part of the bowel).
- People who have an implant such as a stent or catheter located less than 1 cm from the area to be treated.
- People who have an abnormal opening or passage (fistula) in the urinary tract or rectum.
- People with scarring, narrowing, or other problems in or around the anal or rectal area that would make it difficult to insert the treatment device.
- People with structural abnormalities of the rectum or its lining.
- People who have an artificial sphincter, a penile implant, or an implant within the prostate such as a stent.
- People with a history of inflammatory bowel disease (such as Crohn's disease or ulcerative colitis).
- People who currently have an active infection of the urinary or genital area.
- People who have a known severe allergy to latex.
- People for whom anaesthesia is not considered safe (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sébastien Crouzet, Pr, Service d'Urologie et Chirurgie de la Transplantation - Hôpital Edouard Herriot - Hospices Civils de Lyon
Phone: 04 72 11 03 25
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The percentage of analyses that could be completed for each of the three HIFU necrosis detection techniques
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.